Publications
- Minimal residual disease detectable by quantitative assessment of WT1 gene before allogeneic stem cell transplantation in patients in first remission of acute myeloid leukemia has an impact on their future prognosis2013 | First Faculty of Medicine
- Is FLT3 internal tandem duplication significant indicator for allogeneic transplantation in acute myeloid leukemia? An analysis of patients from the Czech Acute Leukemia Clinical Register (ALERT)2007 | First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Is FLT3 internal tandem duplication significant indicator for allogeneic transplantation in acute myeloid leukemia? : an analysis of patients from the Czech Acute Leukemia Clinical Register (ALERT)2007 | First Faculty of Medicine
- Steroid-refractory acute graft-versus-host disease2007 | First Faculty of Medicine
- Acute myeloid leukemia: what is new in the treatment of this disease occuring usually in older adults?2007 | First Faculty of Medicine
- Decreased risk of acute gastrointestinal toxicity when substituting methotrexate with mycophenolate mofetil in the prevention of graft-versus-host disease in stem cell transplantation following myeloablative conditioning regimens2006 | First Faculty of Medicine
- Low levels of minimal residual disease after induction chemotherapy for BCR-ABL1-negative acute lymphoblastic leukaemia in adults are clinically relevant2022 | First Faculty of Medicine, Second Faculty of Medicine
- A validation study of potential prognostic DNA methylation biomarkers in patients with acute myeloid leukemia using a custom DNA methylation sequencing panel2022 | First Faculty of Medicine, Faculty of Science
- WT1 Gene Expression in Peripheral Blood Before and After Allogeneic Stem Cell Transplantation is a Clinically Relevant Prognostic Marker in AML - A Single-center 14-year Experience2021 | First Faculty of Medicine
- WT1 Expression in Peripheral Blood at Diagnosis and During the Course of Early Consolidation Treatment Correlates With Survival in Patients With Intermediate and Poor-Risk Acute Myeloid Leukemia2020 | First Faculty of Medicine
Loading network view...